Ether

Ether

SCHEMBL5326237

CCOCC.c1ncncn1

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrimidine SCHEMBL1766108 0.84 TSHR (0.30)
Pyrazine SCHEMBL2492066 0.79 ALDH1A1 (0.33) ALDH1A1
Ether SCHEMBL9248674 0.76 ALDH1A1 (0.47) ALDH1A1
Ether SCHEMBL21406 0.76 ALDH1A1 (0.47) ALDH1A1
Ether SCHEMBL9248046 0.76 ALDH1A1 (0.47) ALDH1A1
Ether SCHEMBL6 0.76
Ether SCHEMBL8160191 0.76 ALDH1A1 (0.47) ALDH1A1
Benzene SCHEMBL665216 0.72 ALDH1A1 (0.39) ALDH1A1
Benzene SCHEMBL9989943 0.72 ALDH1A1 (0.39) ALDH1A1
Ether SCHEMBL27546779 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070111027-A1 Light-emitting organic materials NATIONAL SCIENCE FOUNDATION 2007-05-17 US disclosed
WO-2007016454-A2 LIGHT-EMITTING ORGANIC MATERIALS UNIVERSITY OF ROCHESTER (US) 2007-02-08 WO disclosed
EP-1549645-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) 2005-07-06 EP disclosed
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-06-10 US disclosed
WO-2004031184-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) 2004-04-15 WO disclosed
US-5322528-A Reducing agent precursors TEXACO INC. (US) 1994-06-21 US disclosed
EP-0564233-A1 Composition of matter for high temperature phenolphthalein-, phenolphthalide-, fluorene-, xanthane-, and anthrone-S-triazines that are soluble in diesel fuel TEXACO DEVELOPMENT CORPORATION (US) 1993-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors TIE1, KDR, FLT1 ALDH1A1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.